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Introduction
MANP is a novel natriuretic peptide developed at the
Mayo Clinic following its discovery from a familial frame-
shift mutation of the atrial natriuretic peptide (ANP) gene
(NPPA) [1,2]. MANP possesses the 28 amino acid (AA)
core structure of ANP with a novel 12 AA extended C-
terminus resulting in a 40 AA peptide. MANP activates
the particulate guanylyl cyclase A (pGC-A) receptor with
equal potency to ANP and is highly resistant to degrada-
tion by neprilysin. In vivo, MANP has greater and longer
lasting blood pressure (BP) lowering, natriuretic and aldos-
terone suppressing actions than ANP [3]. In animal mod-
els of hypertension, MANP potently reduces BP and
enhances renal function while in experimental hyperten-
sive heart failure, MANP has more potent renal and aldos-
terone suppressing actions than the cyclic guanylyl
monophosphate (cGMP)-activating therapeutic agent
nitroglycerin [4]. In vivo administered subcutaneously,
MANP activates plasma cGMP 10-fold greater than ANP
with a 4-fold greater half-life [3,4]. Based upon its potent
cGMP mediated cardiorenal actions and studies which
suggest that human hypertension may represent a relative
natriuretic peptide deficiency state, MANP is being devel-
oped for treatment of severe resistant hypertension.
Methods and results
MANP (ZD100, Zumbro Discovery) recently entered a
first in human trial in patients with hypertension. A Phase
1 (Part A) single ascending dose (SAD) study was recently
completed. One dose of MANP was administered to
hypertensive patients in whom anti-hypertensives were
stopped for two weeks prior to MANP administration.
Three cohorts of 4 subjects were studied (1, 2.5 and
5 ug/kg subcutaneous injection) with dose escalation
stopped if more than two subjects had greater than
30 mmHg reduction in systolic BP. Endpoints were safety,
BP, pharmacokinetics, renal actions and neurohumoral
function. Initial BP and safety data will be presented for
the first time.
Conclusion
MANP is a novel, sustained-acting pGC/cGMP activating
peptide, which goes beyond ANP in reducing BP, aug-
menting renal function and suppressing aldosterone. BP
and safety data will be presented for the first time from
the recently completed first in human SAD study in
patients with hypertension.
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